Cargando…

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics

Here, we used an informatics-based approach to identify novel biomarkers of overall survival and tumor progression in non-small cell lung cancer (NSCLC) patients. We determined whether nuclear-encoded genes associated with mitochondrial biogenesis and function can be used to effectively predict clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sotgia, Federica, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620239/ https://www.ncbi.nlm.nih.gov/pubmed/28978099 http://dx.doi.org/10.18632/oncotarget.19677

Ejemplares similares

Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine
por: Sotgia, Federica, et al.
Publicado: (2017)

Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy
por: Sotgia, Federica, et al.
Publicado: (2017)

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival
por: Wang, Zhaoxi, et al.
Publicado: (2015)

Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?
por: Sotgia, Federica, et al.
Publicado: (2011)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant
por: Farnie, Gillian, et al.
Publicado: (2015)

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis
por: Ozsvari, Bela, et al.
Publicado: (2017)

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
por: Fiorillo, Marco, et al.
Publicado: (2019)

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
por: Bonuccelli, Gloria, et al.
Publicado: (2018)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Šutić, Maja, et al.
Publicado: (2021)

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
por: Peiris-Pagès, Maria, et al.
Publicado: (2018)

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients
por: Catarino, Raquel, et al.
Publicado: (2012)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo, Matthew Z, et al.
Publicado: (2021)

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
por: Plönes, Till, et al.
Publicado: (2016)

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features
por: Peiris‐Pagès, Maria, et al.
Publicado: (2019)

Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity
por: Sánchez-Alvarez, Rosa, et al.
Publicado: (2020)

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

Using the common cold virus as a naturally occurring vaccine to prevent COVID-19: Lessons from Edward Jenner
por: Sotgia, Federica, et al.
Publicado: (2020)

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017)

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy
por: Fiorillo, Marco, et al.
Publicado: (2018)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2017)

Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
por: Sato, Yoshiharu
Publicado: (2022)

The Reproducibility of Histopathologic Assessments of Programmed Cell Death-Ligand 1 Using Companion Diagnostics in NSCLC
por: Yuan, Pei, et al.
Publicado: (2020)

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou, Niki, et al.
Publicado: (2014)

Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
por: Del Valle, Luis, et al.
Publicado: (2021)

Three Markers in Cancerous and Healthy Cells of Patients with Non-Small-Cell Lung Carcinoma (NSCLC)
por: Jamaati, Hamidreza, et al.
Publicado: (2019)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group
por: Dietel, Manfred, et al.
Publicado: (2016)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Hallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
por: Sotgia, Federica, et al.
Publicado: (2019)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds
por: Ózsvári, Béla, et al.
Publicado: (2020)

COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
por: Sargiacomo, Camillo, et al.
Publicado: (2020)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival
por: Sausville, Lindsay N., et al.
Publicado: (2017)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
por: Brueckl, Wolfgang M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r8eu65sgj4oss954ok08j73tob